OBJECTIVE This study aimed to explore the expression and significance of transforming growth factor β1（TGF-β1）,extracellular signal-regulated kinases 1/2 （ERK1/2）, and K-ras in colorectal cancer （CRC） using ti...OBJECTIVE This study aimed to explore the expression and significance of transforming growth factor β1（TGF-β1）,extracellular signal-regulated kinases 1/2 （ERK1/2）, and K-ras in colorectal cancer （CRC） using tissue microarray technology.METHODS The expressions of TGF-β1, ERK1/2, and K-ras in colon cancer cells taken from the specimens of 92 CRC patients （stage Ⅰ： 16 cases, stage Ⅱ： 28 cases, stage Ⅲ： 24 cases, and stage Ⅳ：24 cases） were analyzed using tissue microarray technology and immunohistochemistry, and compared with those of 20 normal colon tissue samples.RESULTS High immunoreactive scores （IRS） of TGF-β1,p-ERK1/2, and K-ras protein in CRC were obtained, which were 66.3% （61/92）, 59.8% （55/92）, and 48.9% （45/92）, respectively, and those in normal epithelial cells of colon were 10% （2/20）, 20% （4/20）, and 30% （6/20）, respectively （P 〈 0.05）. The expressions of TGF-β1 and ERK1/2 in CRC at stage Ⅰwere 37.5% and 31.3%,respectively, and those in CRC at stage Ⅳ were 83.3% and79.3%, respectively, with statistically significant differences. No significant relationship was found between K-ras expression and tumor stages （P〉0.05）.CONCLUSION High level expressions of TGF-β1 and ERK1/2 are closely related to the clinical stages of colon cancer and crosstalk may exist between the 2 signal pathways.展开更多
基金This work was supported by grants from Soochow University Students Innovation Foundation （No. 5731512810）, Chinese National Natural Science Foundation （No.81072186）, and Jiangsu Provincial Higher Institution Natural Science Foundation （No.10KJB320018）.
文摘OBJECTIVE This study aimed to explore the expression and significance of transforming growth factor β1（TGF-β1）,extracellular signal-regulated kinases 1/2 （ERK1/2）, and K-ras in colorectal cancer （CRC） using tissue microarray technology.METHODS The expressions of TGF-β1, ERK1/2, and K-ras in colon cancer cells taken from the specimens of 92 CRC patients （stage Ⅰ： 16 cases, stage Ⅱ： 28 cases, stage Ⅲ： 24 cases, and stage Ⅳ：24 cases） were analyzed using tissue microarray technology and immunohistochemistry, and compared with those of 20 normal colon tissue samples.RESULTS High immunoreactive scores （IRS） of TGF-β1,p-ERK1/2, and K-ras protein in CRC were obtained, which were 66.3% （61/92）, 59.8% （55/92）, and 48.9% （45/92）, respectively, and those in normal epithelial cells of colon were 10% （2/20）, 20% （4/20）, and 30% （6/20）, respectively （P 〈 0.05）. The expressions of TGF-β1 and ERK1/2 in CRC at stage Ⅰwere 37.5% and 31.3%,respectively, and those in CRC at stage Ⅳ were 83.3% and79.3%, respectively, with statistically significant differences. No significant relationship was found between K-ras expression and tumor stages （P〉0.05）.CONCLUSION High level expressions of TGF-β1 and ERK1/2 are closely related to the clinical stages of colon cancer and crosstalk may exist between the 2 signal pathways.
